Iantrek develops minimally invasive surgical technologies and biologic tissue solutions aimed at restoring the eye’s natural fluid outflow pathways to treat chronic eye diseases such as glaucoma. The company launched its lead commercial product, AlloFlo Uveo, in October 2025 and has introduced AlloSpan Canal in the U.S. Iantrek positions its portfolio to offer complementary surgical solutions targeting both natural outflow pathways for a more comprehensive, physiologic approach to glaucoma intervention. Following a Series C in 2025 led by USVP, Sectoral, aMoon, and Visionary Ventures, Iantrek secured a $30 million debt facility from Trinity Capital to accelerate commercial expansion and advance its pipeline and regulatory work. The company plans to scale manufacturing and distribution capabilities and strengthen market access to broaden physician and patient adoption.

Total raised

$95M

Funding rounds

3

Latest round

Equity

Latest activity

Apr 2026